Apollo logo

Addressing the Polypharmacy Challenge in Older People

The Polypharmacy Challenge Blog

Tackling Polypharmacy and Multimorbidity: Reflections on SAPC 2017

I have just returned from the annual scientific meeting of the Society for Academic Primary Care (SAPC), which was held at Warwick University last week. The central concerns of the APOLLO-MM project - multimorbidity and polypharmacy – featured prominently in this year’s meeting. This may seem unsurprising given that care of patients with multimorbidity is very much the ‘norm’ for the generalist medical practitioner. But it was encouraging to see an increasing emphasis on how to account for the complexity of multimorbidity in research contexts, and there is certainly a growing army of researchers trying to tackle ‘inappropriate’ polypharmacy.

One thing that became clear as I moved from presentation to presentation about polypharmacy is just how ‘baggy’ some of our definitions are. Researchers use a range of cut-off points to define polypharmacy (4+, 5+, 10+, 15+ medicines). They do so whilst acknowledging that definitions based on numbers alone are crude and inadequate, as these measures conceal crucial issues such as: the poor alignment between numbers of drugs prescribed, dispensed and consumed; the contribution of non-prescribed medicines to the medicines count; and the relative complexity of different medicines regimens to the individual patient. The terms ‘appropriate’ and ‘inappropriate’ which are frequent qualifiers of the ‘polypharmacy’ concept are widely used but beg further questions such as ‘appropriate to whom?’ and “appropriate for what purpose or with what in mind?” and cause us to stop and wonder how fixed and certain are these notions of appropriateness.

Polypharmacy perspectives

Over this week we will be publishing guest blog posts from four different perspectives on polypharmacy from our project launch speakers. We asked them each to speak about why the APOLLO-MM research project and research on polypharmacy is so important.

First up, Roger Jones discusses the relationship between polypharmacy and multi-morbidity and the need for a new therapeutic research paradigm, which embraces complex disease and patient preferences, providing more useful, real-world guidance on chronic disease management.

It was a privilege to be asked to speak at the launch of the APOLLO-MM project – not the space probe, but something just as exciting. Understanding how to live with – and without – polypharmacy is a major health challenge, and this new research initiative looks set to make real progress in this crucial area.

Polypharmacy is, of course, mostly a result of the mushrooming problem of comorbidity. As we get older


Show more posts

Subscribe to receive our latest blog post

* indicates required
Queen Mary University of London logo
NIHR stamps without NHS logo
Barts and The London School of Medicine and Dentistry Queen Mary University of London logo